MedTrace Logo

A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation

NCT02333513 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2015-04-09

No results posted yet for this study

Summary

This trial is aimed at evaluating the safety and effectiveness of PCV chemotherapy in patients with recurrent high-grade glioma with IDH1/2 mutation.

Conditions

  • Recurrent High-grade Glioma

Interventions

DRUG

Lomustine/Vincristine/Procarbazine

Sponsors & Collaborators

  • Beijing Tiantan Hospital

    collaborator OTHER

  • Hebei Yanda Hospital

    lead OTHER

Principal Investigators

  • Nan Ji, Medical Doctor · Beijing Tiantan Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02333513 on ClinicalTrials.gov